Premium
Hybrid leukaemia of T cell and myeloid lineages: cytogenetic distinction from second (induced) malignancy
Author(s) -
Simpson E. M.,
Mott M. G.
Publication year - 1987
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1987.tb04140.x
Subject(s) - malignancy , somatic evolution in cancer , myeloid , cytogenetics , biology , chemotherapy , cancer research , acute lymphocytic leukemia , lineage (genetic) , immunology , leukemia , karyotype , chromosome , pathology , medicine , lymphoblastic leukemia , genetics , cancer , gene
Summary . The therapeutic and prognostic implications of relapse and clonal evolution of leukaemia are substantially different from those of secondary (induced) malignancy. This report documents the case of a patient who presented with apparent acute non‐lymphocytic leukaemia (ANLL) following therapy for acute (T‐cell) lymphoblastic leukaemia (ALL) 4 years previously. Morphologically and cytochemically the cells were of myeloid type, but the cell markers showed a T cell lineage. Cytogenetic studies confirmed that this was a relapse of T cell ALL with a phenotypic change, rather than a second malignancy induced by chemotherapy. A 14q deletion present at initial diagnosis recurred at relapse, with the addition of cells with complete deletion of chromosome 14, indicating clonal evolution.